Details for Patent: 12,194,150

« Back to Dashboard

Which drugs does patent 12,194,150 protect, and when does it expire?

Patent 12,194,150 protects CREXONT and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 12,194,150

Title:	Levodopa dosing regimen
Abstract:	The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.
Inventor(s):	Richard D'Souza, Hester Visser, Suneel Gupta
Assignee:	Amneal Pharmaceuticals LLC
Application Number:	US17/558,337
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,194,150
Patent Claim Types: see list of patent claims	Use; Device; Dosage form;

Drugs Protected by US Patent 12,194,150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-001	Aug 7, 2024		RX	Yes	No	12,194,150					TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-002	Aug 7, 2024		RX	Yes	No	12,194,150					TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-003	Aug 7, 2024		RX	Yes	No	12,194,150					TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-004	Aug 7, 2024		RX	Yes	Yes	12,194,150					TREATMENT OF PARKINSON'S DISEASE

International Family Members for US Patent 12,194,150

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3196650
China	116801869
Colombia	2023009085
European Patent Office	4267113
Japan	2024501235
South Korea	20230124622